Clinical Trial Update: Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

The document notes a completed Phase 1/Phase 2 study evaluating AT-101 in combination with topotecan for relapsed/refractory small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• AT-101 (gossypol acetic acid)
• Topotecan (topotecan)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED